InvestorsHub Logo
Followers 127
Posts 3172
Boards Moderated 0
Alias Born 08/24/2015

Re: AVII77 post# 55221

Sunday, 02/28/2016 7:43:34 AM

Sunday, February 28, 2016 7:43:34 AM

Post# of 704160
You're dodging the issue here. Of course everyone gets surgical resection. But the study you site is about secondary resection after progression, and this is muddying the waters. You've been touting your claim of the trial being full of pseudoprogressors in the info arm. So what? That's why P3 trials are done, to weed out the inference from the reality. How do you know the study you sited with secondary resection wasn't also full of pseudoprogressors?

More relevant comparison? Why do I need to do that? Maybe there isn't one; again, P3 trial results are the gold standard. If we're going to infer I feel we should infer from the known science, not what we feel about what is pseudoprogression and what isn't; we're not sure, and no one has come up with a definitive criterion to describe it. Until then we're stuck with the current internationally accepted way of defining it in ongoing trials.

I don't care about Bosch's claims, nor do I care about Brandes or Roldan. I didn't study that whole issue. I don't have to critique each and every issue to justify my claim that you made a baseless comparison. There's more evidence to dig into with the science behind the treatment than there is from digging into comparisons of P1 trials to other informational studies. The science, in my opinion, provides much more insight to the possible results than the continuing manipulation of statistics and the incessant and obsessive issue of pseudoprogression. We know it's an issue, and we know the entire scientific community is trying to find a way to deal with it's possible mucking of the data in GBM trials. Unless the entire NWBO cohort is pseudoprogressors the final data should be able to prove if DCVax works or not. Data can be misleading for or against, and the only way to figure out what's what is to be patient and pursue the truth. Speculating that NWBO is out to manipulate the data to create a false impression, all the while under the watchful microscope of the FDA, is preposterous and cynical. It either works or it doesn't, but to have the data show it doesn't when it actually does is even worse than the opposite. I choose to have a little more faith in the process.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News